Drug Target Review

JUNE 2, 2025

Shaping Lonzas leadership in bioconjugates Bertholjotti has been with the company for over 30 years, witnessing and actively contributing to its transformation from a traditional small molecule manufacturer into a global leader in contract development and manufacturing (CDMO) for biopharmaceuticals, including bioconjugates.

Small Molecule 52

Small Molecule Engineering Therapies Drugs 52

Drug Target Review

JUNE 11, 2025

Unimodality does not allow for mixing data: cell data, images, molecular data, clinical data records, small molecule descriptors, ADME Tox data, transcriptomic data, text-based drug and disease representations, clinical trial protocols, publications and patent data, etc.

Drugs 65

Drugs Clinical Trials Drug Development Pharmaceuticals 65

Drug Target Review

APRIL 7, 2025

Advancements in screening technologies for small-molecule drug discovery including cellular assays, computational screening, and biophysics-based methods enhanced by structural biology breakthroughs have improved screening hit rates and facilitated the identification of drug candidates for previously undruggable targets.

Fragment Screening 52

Fragment Screening Drugs Biophysical Assays Small Molecule 52

Drug Target Review

DECEMBER 4, 2024

In addition to generating agonistic antibodies, Confo is also successfully applying the ConfoBody/ConfoChimer technology to drugging GPCR with small molecules. They are now applying the same strategy to a range of GPCRs with a focus on high value targets in obesity and other metabolic conditions.

Small Molecule 123

Small Molecule Pharmacokinetics Therapies Immune Response 123

Drug Patent Watch

JANUARY 13, 2025

As we delve into the intricate world of biosimilar market dynamics, we’ll explore how these complex molecules are reshaping treatment paradigms across diverse patient populations. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4

Biosimilars 61

Biosimilars Marketing Treatment Small Molecule 61

The Pharma Data

JUNE 9, 2025

Pimicotinib: A Promising CSF-1R Inhibitor Pimicotinib is an investigational small molecule developed by Abbisko Therapeutics Co., Food and Drug Administration, with additional filings planned in other markets.” In parallel, we are working to file a New Drug Application (NDA) to the U.S.

Treatment 40

Treatment Therapies Small Molecule Marketing 40

The Pharma Data

JUNE 24, 2025

This expanded partnership reflects Bayer’s ongoing commitment to strengthening its presence in China—home to the world’s second-largest pharmaceutical market—and underscores its strategic vision to bolster healthcare innovation through cross-sector collaboration.

Pharma R&D 40

Pharma R&D Pharmaceutical Companies Pharmaceuticals Science 40

LifeSciVC

JULY 8, 2025

This growing complexity gives rise to a deeper set of questions, ones that extend beyond infrastructure and markets. One team might be working on a cell therapy, another on RNA, another on small molecules. They concern how we build companies, how we design teams, and how we lead amid shifting forms of pressure and constraint.

Hospitals 54

Hospitals Small Molecule Science Nurses 54

FDA Law Blog: Biosimilars

JULY 2, 2025

Reviewing test protocols and reports for small molecule or biologic drug programs. Meeting with FDA on behalf of clients or assisting clients seeking marketing authorization in preparing to meet with FDA and in other interactions with the Agency. Specifically, manufacturing/testing procedures and compliance with cGMPs.

Small Molecule 52

Small Molecule Compliance Engineering FDA 52

New Drug Approvals

APRIL 18, 2025

Originator Sanofi Developer Neurocrine Biosciences; Sanofi Class Amines; Antidepressants; Anxiolytics; Chlorobenzenes; Cyclopropanes; Fluorobenzenes; Halogenated hydrocarbons; Phenyl ethers; Small molecules; Thiazines; Thiazoles Mechanism of Action Corticotropin releasing factor receptor 1 antagonists Orphan Drug Status Yes – Congenital adrenal (..)

FDA 62

FDA FDA Approval Drugs Trials 62

Molecular Design

DECEMBER 31, 2024

My pulse will be quickenin' With each drop of strychnine We feed to a pigeon It just takes a smidgin To poison a pigeon in the park Tom Lehrer, Poisoning Pigeons in the Park | video ** Ill be reviewing the H2024 study (Occurrence of Natural Selection in Successful Small Molecule Drug Discovery) in this post.

Small Molecule 85

Small Molecule Drugs Production Science 85

Codon

JULY 17, 2025

In addition, upward of 20 wholesale drug firms are marketing the compound, which suggests that a considerable population is being medicated. Unlike hundreds of other purported weight loss drugs on the market at the time — from dangerous Jad Salts to Marmola (a “thyroid substance”) — DNP actually worked.

Drugs 69

Drugs Doctors Clinical Trials Production 69

Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. The global ADC market is expected to continue this steep upward trajectory and is anticipated to exceed $16 Billion by 2026. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

LifeSciVC

JANUARY 16, 2024

The market for each target class likely asymptotes with the number of Pharma or large biotech who can clinically develop and commercialize such assets; thus, there is intense focus on the first handful of assets to market. Small molecule GLP1s?

Small Molecule 143

Small Molecule Trials Therapies Disease 143

Drug Target Review

JULY 23, 2024

This laid the groundwork for my career in drug discovery using novel modalities like small molecule inhibitors, antibodies, RNA interference (RNAi) and, currently, small molecule protein degraders – which are opportunities to change how we think about medicines.

Small Molecule 116

Small Molecule Targeted Protein Degradation Science Disease 116

Alta Sciences

NOVEMBER 5, 2024

And when it’s time to go to market, the scale-up of the manufacturing process for commercialization is straightforward. Because of these qualities, liquid-filled hard capsules offer a great opportunity for line extensions, and brand differentiation, in the competitive pharma market. Why Liquid-Filled, Hard-Shell Capsules?

Marketing 52

Marketing Small Molecule Pharmaceuticals Production 52

ASPET

SEPTEMBER 7, 2023

Avalglucosidase alfa has received marketing authorization in several countries for infantile-onset and/or late-onset Pompe disease. This recently approved enzyme replacement therapy (ERT) was glycoengineered to maximize CIMPR binding through high-affinity interactions with ~7 bis-M6P moieties.

Small Molecule 100

Small Molecule Therapies Disease Treatment 100

The Pharma Data

NOVEMBER 19, 2020

The Company is also aiming to leverage the highly conserved structure of the SARS-CoV-2 M pro protease as a basis for the design of novel oral small molecules against predicted future variants of SARS-CoV-2 and other related human viruses.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. The lead candidate, HTL0022562, has advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials. Vlad Coric , M.D.,

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

SEPTEMBER 10, 2021

This is the first marketing authorization globally for abrocitinib-. This is the first marketing authorization globally for abrocitinib-. This is the first marketing authorization worldwide for this treatment. “We CIBINQO (abrocitinib) is an oral small molecule that selectively inhibits Janus kinase (JAK) 1.

Marketing 52

Marketing Licensing Licensing Small Molecule 52

DrugBank

OCTOBER 17, 2024

By utilizing high-resolution protein structures obtained through X-ray crystallography, researchers could design small molecules that potently inhibit the SARS-CoV-2 main protease, a key enzyme essential for viral replication.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

The Premier Consulting Blog

NOVEMBER 20, 2024

In the case of urgent or immediate public interest, process validation may be conducted concurrently with manufacturing the commercial small molecule or biologic product to expedite product availability for patients.

Small Molecule 52

Small Molecule Drugs FDA Production 52

The Pharma Data

JUNE 22, 2023

Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan SANTA MONICA, Calif.–(BUSINESS in December 2022 about changes to their initial 2017 partnership whereby Daiichi Sankyo obtained the Marketing Authorization for Yescarta ®. –(BUSINESS WIRE)– Kite Pharma, Inc.,

Therapies 40

Therapies Marketing Small Molecule Science 40

Conversations in Drug Development Trends

APRIL 4, 2024

Stability Tests: For small molecule, only -20°C stability testing is required, while large molecule need both -20°C and -70°C tests if samples are intended for storage at these temperatures. Select the right partner with experience meeting regulatory standards for all target markets.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

Alta Sciences

FEBRUARY 10, 2025

As a leading CRO, we provide a suite of unparalleled services designed to streamline your path to market. Contact us to get started!

Small Molecule 52

Small Molecule Clinical Trials Drug Development Trials 52

The Pharma Data

NOVEMBER 22, 2020

SAN DIEGO–( BUSINESS WIRE )– Vividion Therapeutics , a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, today announced that Jeffrey Hatfield has been appointed as the company’s chief executive officer. market access. 23, 2020 13:30 UTC.

Small Molecule 52

Small Molecule Pharmacy Pharmaceuticals Doctors 52

Nvidia Developer: Drug Discovery

MARCH 21, 2023

Creating new drug candidates is a heroic endeavor, often taking over 10 years to bring a drug to market. Creating new drug candidates is a heroic endeavor, often taking over 10 years to bring a drug to market. These state-of-the-art AI models help generate de novo proteins and molecules and predict the 3D structures of proteins.

Small Molecule 52

Small Molecule Drugs Clinical Trials DNA 52

The Pharma Data

JANUARY 25, 2021

–( BUSINESS WIRE )– Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. 26, 2021 13:00 UTC. FREDERICK, Md.–( About VLX-1005.

FDA 52

FDA Small Molecule FDA Approval Drugs 52

LifeSciVC

APRIL 24, 2024

and whether a molecule’s pharmacology can help to mitigate safety risk. Especially for oligo or small molecule discovery and development, it’s important to understand whether there are highly homologous sequences or proteins that may be impacted by a given therapeutic approach. in liver, in CNS)? Consider Fig.

Production 131

Production Small Molecule Regulations Trials 131

The Pharma Data

AUGUST 7, 2021

Vividion’s platform is able to produce a variety of small molecule therapies across indications, with initial focus on targets relevant to oncology and immunology. The acquisition of Vividion strengthens Bayer’s small molecule capabilities and expands Bayer’s reach into new modalities.

Small Molecule 52

Small Molecule Drugs Therapies Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 29, 2020

(Headquarters: Cambridge, UK, “Wren”) today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target ?-synuclein synuclein for the potential treatment of synucleinopathies including Parkinson’s disease and dementia with Lewy bodies.

Small Molecule 52

Small Molecule Research Pharmaceutical Companies Drugs 52

PerkinElmer

SEPTEMBER 8, 2019

Over the last 20 years, Cisbio has become a leading Life Sciences company which develops, manufactures, and markets high quality kits and reagents for the drug discovery and life science markets used by pharmaceutical, biotechnology, academia and contract research organizations across the globe. Learn more about Cisbio here.

Cell Based Assays 52

Cell Based Assays Small Molecule Science Pharmaceuticals 52

Drug Target Review

JUNE 19, 2024

Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy. Just like small molecules and antibodies, cell therapies are changing how we treat patients.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

LifeSciVC

AUGUST 5, 2024

The Nimbus experience to date is that this merger of scientific disciplines shows less benefit in speed and much clearer benefit in a wider range of tractable drug discovery targets and enhancement in the quality of small molecule clinical candidates developed. a company with the strongest pipeline in the entire industry.”

Molecular Biology 99

Molecular Biology Production Drug Development Small Molecule 99

The Pharma Data

OCTOBER 4, 2021

The GSK structures were collected at different stages of the pharmaceutical pipeline and are not limited to marketed products. The authors at GSK and CCDC completed a robust analysis of the small molecule crystal structures containing X-ray diffraction results from GSK and its heritage companies for the past 40 years.

Small Molecule 52

Small Molecule Drugs Pharmaceuticals Research 52

The Pharma Data

NOVEMBER 26, 2020

This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. Edward Hæggström, Nanoform CEO: “Small is powerful, also in Bio! ” Prof. Finnish time.

Small Molecule 52

Small Molecule Clinical Trials Marketing Pharmaceuticals 52

The Pharma Data

JUNE 28, 2021

Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. Noria) and PSMA Therapeutics Inc.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52